Patents Represented by Attorney, Agent or Law Firm Raymond J. Lillie
  • Retroviral envelopes having modified hypervariable polyproline regions
    Patent number: 6004798
    Abstract: A retroviral vector particle having a modified retroviral envelope polypeptide. The retroviral envelope polypeptide includes the hypervariable polyproline region, or hinge region, and the hypervariable polyproline region, or hinge region is modified to include a targeting polypeptide including a binding region which binds to a ligand. Such a retroviral vector may be "targeted" to various cells for delivery of genetic material to such cells.
    Type: Grant
    Filed: May 14, 1997
    Date of Patent: December 21, 1999
    Assignee: University of Southern California
    Inventors: W. French Anderson, Bonnie Weimin Wu
  • Targetable vector particles
    Patent number: 5985655
    Abstract: A vector particle (e.g., a retroviral vector particle) containing a chimeric envelope includes a receptor binding region that binds to a receptor of a target cell. The receptor of the target cell is other than the amphotropic cell receptor. The receptor binding region may be a receptor binding region of a human virus. A portion of the envelope gene may be deleted and the deleted portion is replaced with another receptor binding region or ligand. Such vector particles are targetable to a desired target cell or tissue, and may be administered directly to the desired target cell or tissue as part of a gene therapy procedure, or administered directly into the patient.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 16, 1999
    Assignee: The United States of America as represented by the Department of Health and Human Sevices
    Inventors: W. French Anderson, Leon F. Baltrucki, James M. Mason
  • Vehicle seat with safety belt assembly
    Patent number: 5979990
    Abstract: Described is a vehicle seat having a safety belt which can be extended from a belt retractor. The belt retractor is mounted to one side of the vehicle seat. A belt end portion which projects from the belt retractor is provided with a spring hook means. An engagement element for retainingly receiving the spring hook means is disposed at the second side of the vehicle seat.
    Type: Grant
    Filed: November 19, 1998
    Date of Patent: November 9, 1999
    Assignee: Grammer AG
    Inventors: Hermann Meiller, Josef Kohl, Theodor Abels
  • Nucleic acid sequences controlling lung cell-specific gene expression
    Patent number: 5976873
    Abstract: An oligonucleotide which includes at least one nucleic acid sequence which binds to at least one nuclear protein found in lung cells, such as TTF-1 protein. The oligonucleotide may be contained in a vector. The at least one nuclear protein provides for lung cell-specific expression of the vector upon binding of the at least one nucleic acid sequence to the at least one nuclear protein. Such vector may also include genes encoding therapeutic agents, and may be employed for delivering genes encoding therapeutic agents to lung cells.
    Type: Grant
    Filed: May 17, 1995
    Date of Patent: November 2, 1999
    Assignee: Children's Hospital Medical Center
    Inventors: Robert J. Bohinski, Jeffrey A. Whitsett
  • Methods of inhibiting T cell mediated immune responses with humanized LO-CD2A-specific antibodies
    Patent number: 5951983
    Abstract: The present invention relates to a LO-CD2a antibody and methods of using such antibodies or molecules that bind to the same epitope (or a portion thereof) to prevent and inhibit an immune response in human patients, preferably, where the immune response is mediated by the activation and proliferation of T cells or natural killer cells. The administration of an effective amount of the LO-CD2a antibody to a human patient will prevent or inhibit graft rejection, graft versus host disease or autoimmune disease.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: September 14, 1999
    Assignees: Universite Catholique de Louvain, Bio Transplant, Inc.
    Inventors: Herve Bazin, Dominique Latinne, Ruth Kaplan, Thomas Kieber-Emmons, Christina E. Postema, Mary E. White-Scharf
  • Retroviral vectors produced by producer cell lines resistant to lysis by human serum
    Patent number: 5952225
    Abstract: Retroviral which are resistant to inactivation by human serum. The retroviral vectors are produced in a cell line which is resistant to lysis by human serum, such cell lines including the HOS, Mv-1-Lu, HT1080, TE671, and human 293 cell lines, as well as cell lines derived therefrom. Such retroviral vectors are especially useful as in vivo gene delivery vehicles.
    Type: Grant
    Filed: August 17, 1995
    Date of Patent: September 14, 1999
    Assignees: Genetic Therapy, Inc., Institute of Cancer Research Royal Cancer Hospital
    Inventors: Michael Pensiero, Mary K. L. Collins, Francois-Loic Cosset, Yasuhiro Takeuchi, Robin A. Weiss
  • Vehicle seat armrest
    Patent number: 5941603
    Abstract: In an armrest arrangement for a vehicle seat the armrest member, for adjustment in respect of height and for simultaneous adjustment in the longitudinal direction of the seat, is connected to a pivot comprising first and second pivot levers which are at least approximately parallel to each other. The end portions of the first and second pivot levers, which are towards the armrest member, are connected together by a first element by associated first and second connecting shafts. The armrest is connected by a second element to the end portion of the second pivot lever, which is towards the armrest member. The first and second elements are detachably fixed together by an arresting member.
    Type: Grant
    Filed: December 31, 1997
    Date of Patent: August 24, 1999
    Assignee: Grammer AG
    Inventor: Dietmar Wein
  • Adenoviral vectors for treatment of hemophilia
    Patent number: 5935935
    Abstract: An adenoviral vector including at least one DNA sequence encoding a clotting factor, such as, for example, Factor VIII, or Factor IX. Such vectors may be administered to a host in an amount effective to treat hemophilia in the host. The vectors infect hepatocytes very efficiently, whereby the hepatocytes express the DNA sequence encoding the clotting factor.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: August 10, 1999
    Assignee: Genetic Therapy, Inc.
    Inventors: Sheila Connelly, Michael Kaleko, Theodore Smith
  • Vectors including foreign genes and negative selective markers
    Patent number: 5925345
    Abstract: A vector, in particular a retroviral vector, which includes a heterologous or foreign gene and a gene encoding a negative selective marker. The negative selective marker enables one to kill cells which contain the gene encoding the negative selective marker, when a particular agent is administered to such cells.
    Type: Grant
    Filed: May 25, 1995
    Date of Patent: July 20, 1999
    Assignees: Genetic Therapy, Inc., The United States of America as represented by the Department of Health and Human Services
    Inventors: Michael Blaese, W. French Anderson, Jeanne R. McLachlin, Yawen L. Chiang, Martin Eglitis
  • Adenoviruses having altered hexon proteins
    Patent number: 5922315
    Abstract: An adenovirus wherein at least one portion of at least one loop region of the hexon is changed. In one embodiment, the adenovirus, prior to modification, is of a first serotype, and at least a portion of at least one loop region of the hexon is removed and replaced with at least a portion of at least one loop region of the hexon of an adenovirus of a second serotype. Such modified adenoviruses do not have epitopes which are recognized by neutralizing antibodies to the unmodified adenovirus of the first serotype.
    Type: Grant
    Filed: January 24, 1997
    Date of Patent: July 13, 1999
    Assignee: Genetic Therapy, Inc.
    Inventor: Soumitra Roy
  • Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
    Patent number: 5912013
    Abstract: The present invention relates to a composition and method of treating a patient by administering carbamazepine in a pharmaceutical dosage form capable of maintaining the patient's blood concentration at from about 4 .mu.g/ml to about 12 .mu.g/ml over at least a 12 hour period, where the blood concentration of carbamazepine does not vary by more than 60 percent.
    Type: Grant
    Filed: April 21, 1995
    Date of Patent: June 15, 1999
    Assignee: Shire Laboratories, Inc.
    Inventors: Edward M. Rudnic, George W. Belendiuk, John McCarty, Sandra Wassink, Richard A. Couch
  • Detection of prostate and other cancers by assaying for cancer-specific antigens having linked oligosaccharides which are at least triantennary
    Patent number: 5902725
    Abstract: A process for assaying for cancer of the prostate, comprising assaying a sample derived from a human for prostate specific antigen having a linked oligosaccharide which is at least triantennary. The assay may employ a binding molecule which binds to oligosaccharides that are at least triantennary, but does not bind to oligosaccharides that are monoantennary or diantennary. Such binding molecule may be a lectin such as PHA-L or an antibody to an oligosaccharide that is at least triantennary.
    Type: Grant
    Filed: July 2, 1997
    Date of Patent: May 11, 1999
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Phillips W. Robbins, Sadhana Prakash
  • Production of polyorganophosphazenes having desired molecular weights
    Patent number: 5869016
    Abstract: A method for producing a polyorganophosphazene, such as, for example, poly?di(carboxylatophenoxy)phosphazenel!, from polydichlorophosphazene. The polydichlorophosphazene is reacted with at least one nucleophilic reagent at a defined molar ratio of the at least one nucleophilic reagent to the polydichlorophosphazene. Such process results in the production of a polyorganophosphazene having a molecular weight within a desired range.
    Type: Grant
    Filed: June 18, 1997
    Date of Patent: February 9, 1999
    Assignee: Virus Research Institute, Inc.
    Inventors: Alexander K. Andrianov, Mark P. LeGolvan, Yuri Svirkin, Sameer S. Sule
  • Determination and identification of active compounds in a compound library
    Patent number: 5866334
    Abstract: Libraries of compounds such as nucleic acids or peptides are contacted with a target molecule and libraries that have at least one compound that bind with at least a minimum activity are determined by a reiterative process in which a change in the rate of recovery (elimination) of compounds that bind to the target indicates that the library contains such a compound. The procedure may also be used to determine indirectly the sequence of such compound by employing sublibraries, each of which have a known entity at a known position of the compound.
    Type: Grant
    Filed: July 16, 1996
    Date of Patent: February 2, 1999
    Assignee: Genzyme Corporation
    Inventor: Bruce A. Beutel
  • Inducing xenograft tolerance and porcine cytokines therefor
    Patent number: 5858963
    Abstract: A method of enhancing tolerance of a porcine transplant in a xenogeneic recipient by administering porcine bone marrow cells to the recipient and of enhancing proliferation and engraftment of the porcine bone marrow cells by exposing said cells to at least one substantially pure porcine cytokine and porcine cytokines that are substantially free of other porcine proteins and preferentially enhance the proliferation and engraftment of porcine bone marrow cells in the presence of bone marrow cells of other species. Protein and DNA sequence(s) for such porcine cytokines.
    Type: Grant
    Filed: May 8, 1995
    Date of Patent: January 12, 1999
    Assignee: BioTransplant, Inc.
    Inventors: Robert J. Hawley, Rodney L. Monroy, Margaret D. Rosa, Bernice Z. Schacter, Paul D. Ronath
  • Purification of polyphosphazene polyacids
    Patent number: 5842471
    Abstract: A method for purification of a polyphosphazene polyacid or acid salt thereof in which a polyphosphazene polyacid or acid salt thereof is dissolved in a concentrated aqueous solution of a salt of monovalent ions. The resulting aqueous solution of the polyphosphazene polyacid or acid salt thereof and the at least one salt of monovalent ions then is diluted to reduce the concentration of the at least one salt of monovalent ions, whereby the polyphosphazene polyacid or acid salt thereof is precipitated. The precipitated polyphosphazene polyacid or acid salt thereof then is recovered.
    Type: Grant
    Filed: May 14, 1997
    Date of Patent: December 1, 1998
    Assignee: Virus Research Institute, Inc.
    Inventors: Alexander K. Andrianov, Mark P. LeGolvan, Yuri Svirkin, Sameer S. Sule
  • Expression of human multidrug resistance genes and improved selection of cells transduced with such genes
    Patent number: 5837536
    Abstract: A DNA sequence for a human mdr1 gene, which encodes p-glycoprotein, wherein at least one base in a splice region of the DNA encoding p-glycoprotein is changed. Such a mutation prevents truncation of the p-glycoprotein upon expression thereof. There is also provided a method of identifying cells which express the human mdr1 gene in a cell population that has been transduced with an expression vehicle including a human mdr1 gene. The method comprises contacting the cell population with a staining material, such as rhodamine 123, and identifying cells which express the human mdr1 gene based on differentiation in color among the cells of the cell population. This method has allowed identification of retroviral producer clones facilitate mdr gene transfer into primary cells. Repopulating hematopoietic stem cells have been genetically engineered with the human mdr1 gene.
    Type: Grant
    Filed: January 5, 1996
    Date of Patent: November 17, 1998
    Assignees: Genetic Therapy, Inc., The United States of America as represented by the Department of Health and Human Services
    Inventors: Kevin T. McDonagh, Arthur Nienhuis, Paul Tolstoshev
  • Methods of inhibiting T-cell medicated immune responses with LO-CD2a-specific antibodies
    Patent number: 5817311
    Abstract: The present invention relates to a LO-CD2a antibody and methods of using such antibodies or molecules that bind to the same epitope (or a portion thereof) to prevent and inhibit an immune response in human patients, preferably, where the immune response is mediated by the activation and proliferation of T cells or natural killer cells. The administration of an effective amount of the LO-CD2a antibody to a human patient will prevent or inhibit graft rejection, graft versus host disease or autoimmune disease.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: October 6, 1998
    Assignee: Universite Catholique de Louvain
    Inventors: Herve Bazin, Dominque Latinne
  • Recovery of polyphosphazene polyacids or acids salts thereof
    Patent number: 5814704
    Abstract: A process for recovering a polyphosphazene polyacid or acid salt obtained by hydrolyzing a polyphosphazene having at least one ester moiety present in at least one substituent group. The polyphosphazene having at least one ester moiety present in at least one substituent group is hydrolyzed with a base in an organic solvent in the presence of water. The water is present in an amount effective to induce the agglomeration of particles of the synthesized polyphosphazene polyacid or acid salt, which enhances the separation of the polyphosphazene polyacid or acid salt from a polymer-free liquid organic phase. The polymer-free liquid organic phase then is separated from the polyphosphazene acid or acid salt, whereby the polyphosphazene acid or acid salt is recovered.
    Type: Grant
    Filed: March 4, 1997
    Date of Patent: September 29, 1998
    Assignee: Virus Research Institute, Inc.
    Inventors: Alexander K. Andrianov, Jonathan R. Sargent, Sameer S. Sule
  • Footwear sole
    Patent number: D417545
    Type: Grant
    Filed: June 2, 1998
    Date of Patent: December 14, 1999
    Inventor: Thomas Senif